Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Posttransplant Lymphoproliferative Disorder”

13 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 13 of 13 results

Testing effectiveness (Phase 2)Study completedNCT02042391
What this trial is testing

Risk-stratified Sequential Treatment of Post-transplant Lymphoproliferative Disease (PTLD) With Rituximab SC and Immunochemotherapy

Who this might be right for
Posttransplant Lymphoproliferative Disorder
Diako Ev. Diakonie-Krankenhaus gemeinnützige GmbH 60
Early research (Phase 1)Ended earlyNCT00469820
What this trial is testing

Vaccine Therapy With or Without Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Multiple Myeloma Undergoing Donor Stem Cell Transplant

Who this might be right for
LeukemiaMultiple Myeloma and Plasma Cell Neoplasm
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 1
Testing effectiveness (Phase 2)Study completedNCT01427881
What this trial is testing

Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

Who this might be right for
Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Megakaryoblastic Leukemia (M7)+65 more
Fred Hutchinson Cancer Center 43
Testing effectiveness (Phase 2)Looking for participantsNCT06954805
What this trial is testing

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

Who this might be right for
LymphomaLymphoma, B-Cell
Jennifer Amengual 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT04554914
What this trial is testing

Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases

Who this might be right for
Epstein-Barr Virus (EBV)-Associated DiseasesEBV+ Lymphoproliferative Disease With Primary Immunodeficiency (EBV+ PID LPD)EBV+ Lymphoproliferative Disease With Acquired (Non-congenital) Immunodeficiency (EBV+ AID LPD)+8 more
Pierre Fabre Medicament
Large-scale testing (Phase 3)Active Not RecruitingNCT05515029
What this trial is testing

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Calcineurin Inhibitor at Patients With Hemoblastosis

Who this might be right for
Acute Lymphoblastic LeukemiaMyeloblastic LeukemiaBiphenotypic Acute Leukemia+3 more
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 56
Testing effectiveness (Phase 2)Study completedNCT00590447
What this trial is testing

Risk Stratified Sequential Treatment for CD20-positive PTLD

Who this might be right for
PTLDPosttransplant Lymphoproliferative Disorder
Charite University, Berlin, Germany 152
Large-scale testing (Phase 3)UnknownNCT04000698
What this trial is testing

Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias

Who this might be right for
Refractory Acute Myeloid LeukemiaRefractory Acute Lymphoblastic Leukemia
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 25
Testing effectiveness (Phase 2)Ended earlyNCT01458548
What this trial is testing

Sequential Treatment of CD20-positive Posttransplant Lymphoproliferative Disorder (PTLD)

Who this might be right for
Post-transplantation Lymphoproliferative Disorder
Charite University, Berlin, Germany 70
Large-scale testing (Phase 3)Looking for participantsNCT06756152
What this trial is testing

Preventing of GVHD with Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Ruxolitinib At Children and Young Adults with Hemoblastosis

Who this might be right for
Biphenotypic Acute LeukemiaAcute Lymphoblastic LeukemiaMyeloblastic Leukemia+3 more
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 50
Testing effectiveness (Phase 2)Looking for participantsNCT06299462
What this trial is testing

PTCy and ATG for MSD and MUD Transplants

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndromes+2 more
Instituto Nacional de Cancer, Brazil 50
Testing effectiveness (Phase 2)Study completedNCT02556931
What this trial is testing

Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaSmall Lymphocytic Lymphoma+11 more
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 117
Large-scale testing (Phase 3)Active Not RecruitingNCT06475820
What this trial is testing

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaBiphenotypic Acute Leukemia+2 more
Federal Research Institute of Pediatric Hematology, Oncology and Immunology 150
190